Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Galvus vildagliptin regulatory update

EMEA's CHMP issued a positive opinion to revise the prescribing information for Galvus vildagliptin from NVS to

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE